ClinicalTrials.gg
CompletedNCT02000947D4190C00006Updated Oct 31, 2019

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

A Phase 1 interventional study of MEDI4736 and Tremelimumab in NSCLC, Non-small Cell Lung Cancer and Lung Cancer, sponsored by MedImmune LLC. Completed at 69 sites in 9 countries. Open to participants aged 18 Years to 101 Years. Per ClinicalTrials.gov, last updated 2019-10-31.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
459
Allocation
Not applicable
Ages
18 Years to 101 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
14th of 94
459 · median 74
Started
2013
the only one that year
Phase 1
13 of 94
1 open now
Registered
1st of 94
by date
Lead sponsor
4 of 94
MedImmune LLC

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 14th largest by enrollment, is the only one that started in 2013, is one of 13 in phase 1, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 101 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).

Read the detailed description

This is a multicenter, open-label, dose-escalation, and dose expansion study of MEDI4736 in combination with tremelimumab to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and antitumor activity of MEDI4736 in combination with tremelimumab in adult subjects with advanced NSCLC.

03

Conditions studied

  • NSCLC
  • Non-small Cell Lung Cancer
  • Lung Cancer

Keywords

  • anti-CTLA-4
  • anti-PD-L1
  • immunotherapy
  • IMTC
04

Who can participate

Ages eligible
18 Years to 101 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Advanced non-small cell lung cancer
  3. (ECOG) performance status of 0-1
  4. Adequate organ and marrow function

Exclusion criteria

Exclusion Criteria:

  1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
  2. Current or prior use of medication within 14 days before the first dose of study drugs
  3. Active or prior documented disease within the last 2 years.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
459 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    MEDI4736 and tremelimumab received by intravenous infusion.

    Drug: MEDI4736 · Drug: Tremelimumab

  • Experimental
    Arm A

    Medi4736 and tremelimumab received by intravenous infusion

    Drug: MEDI4736 · Drug: Tremelimumab

  • Experimental
    Arm B

    MEDI4736 and tremelimumab received by intravenous infusion

    Drug: MEDI4736 · Drug: tremelimumab

  • Experimental
    Arm C

    MEDI4736 and tremelimumab received by intravenous infursion

    Drug: MEDI4736 · Drug: tremelimumab

Interventions

  • MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).

  • Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).

  • Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).

06

What researchers measure

Primary outcomes

  1. Number of subjects reporting adverse events

    The number of subjects reporting adverse events (AEs) and number (percentage) of subjects reporting serious adverse events (SAEs) as graded by CTCAE Version 4.03

    Time frame: Screening through 90 days after the last dose of study medication

  2. Objective response

    Best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as defined as the best response among all overall responses recorded from the start of treatment until progression, or the last evaluable disease assessment in the absence of progressive disease (PD) prior to the initiation of subsequent anti-cancer therapy, or discontinuation from the study, whichever occurs first.

    Time frame: At least 24 weeks as compared to baseline

  3. Number of subjects experiencing dose-limiting toxicities (DLTs)

    The maximum tolerated dose (MTD), which is the highest dose within a cohort where no more than 1 out of 6 subjects experience DLTs or the highest protocol-defined dose for each agent in the absence of exceeding the MTD, will be evaluated using the following safety assessments: adverse events, serious advents, laboratory evaluations, vital signs, physical examinations, and electrocardiogram (ECG) results. Measurements will be aggregated to determine whether a subject has experienced a DLT as assessed by the investigator.

    Time frame: Depending upon the cohort, the DLT evaluation period is from the 1st dose of study medication until (1) the 3rd dose of MEDI4736 and tremelimumab (2) the 2nd dose of MEDI4736 and tremelimumab or (3) the 3rd dose of MEDI4736 and 2nd dose of tremelimumab

Secondary outcomes

  1. Immunogenicity of tremelimumab in combination with MEDI4736

    Immunogenicity of MEDI4736 and tremelimumab will include the number and percentage of subjects who develop detectable anti-drug antibodies (ADAs).

    Time frame: During treatment through study completion, about 2 years

  2. Antitumor activity of tremelimumab in combination with MEDI4736

    Antitumor activity will include objective response (OR) and disease control (DC) based on RECIST Version 1.1, duration of response (DoR), progression-free survival (PFS), and overall survival (OS).

    Time frame: During treatment through study completion, about 2 years

  3. Pharmacokinetic parameters

    Assessment of PK of MEDI4736 and tremelimumab will include individual MEDI4736 and tremelimumab concentrations in serum, and PK parameters including peak concentration (Cmax), area under the concentration-time curve (AUC), clearance (CL), and half-life (t½).

    Time frame: During treatment through study completion, about 2 years

  4. Number of subjects reporting adverse events

    The number of subjects reporting adverse events (AEs) and number (percentage) of subjects reporting serious adverse events (SAEs) as graded by CTCAE Version 4.03

    Time frame: Screening through 90 days after the last dose of study medication

Other outcomes

  1. Biomarkers

    To evaluate biomarkers that may correlate with clinical activity of MEDI4736 in combination with tremelimumab

    Time frame: During treatment through study completion, about 2 years

07

Study locations

69 sites
  • Research Site
    Birmingham, Alabama 35294-3300, United States
  • Research Site
    Tucson, Arizona 85715, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    San Francisco, California 94158, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Lebanon, New Hampshire 03756, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Huntersville, North Carolina 28078, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Portland, Oregon 97213, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77521, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Gosford, 2250, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Bruxelles, 1000, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Liege, 4000, Belgium
  • Research Site
    Bordeaux Cedex, 33076, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    La Tronche, 38043, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Lyon, 69008, France
  • Research Site
    Marseille, 13385, France
  • Research Site
    Montpellier Cedex 5, 34298, France
  • Research Site
    Saint Herblain, 44805, France
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Milano, 20141, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Saronno, 21047, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Sondrio, 23100, Italy
  • Research Site
    Cheongju-si, 28644, Korea, Republic of
  • Research Site
    Incheon, 405-760, Korea, Republic of
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 02841, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 05368, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Seoul, 120-752, Korea, Republic of
  • Research Site
    Seoul, 138-736, Korea, Republic of
  • Research Site
    Barcelona, 08028, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Jaen, 23007, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Malaga, 29730, Spain
  • Research Site
    Sevilla, 41013, Spain
  • Research Site
    Valencia, 46015, Spain
  • Research Site
    Tainan, 704, Taiwan
  • Research Site
    Taipei, 10048, Taiwan
  • Research Site
    London, W1G 6AD, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
08

References and documents

Publications

  • Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, Rizvi NA. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016 Mar;17(3):299-308. doi: 10.1016/S1470-2045(15)00544-6. Epub 2016 Feb 6. PubMed 26858122 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Sep 2019, 70 months.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 70 months is above that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2013
First posted
Dec 4, 2013
StartActual
Oct 25, 2013
Primary completionActual
Sep 17, 2019
CompletionActual
Sep 17, 2019
Last update
Oct 31, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02000947
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Dec 4, 2013
Start date
Oct 25, 2013
Primary completion
Sep 17, 2019
Completion
Sep 17, 2019
Last update
Oct 31, 2019

Study contacts

MedImmune LLC
study director · MedImmune LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion